KR20130108295A - 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 - Google Patents

항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 Download PDF

Info

Publication number
KR20130108295A
KR20130108295A KR1020137006354A KR20137006354A KR20130108295A KR 20130108295 A KR20130108295 A KR 20130108295A KR 1020137006354 A KR1020137006354 A KR 1020137006354A KR 20137006354 A KR20137006354 A KR 20137006354A KR 20130108295 A KR20130108295 A KR 20130108295A
Authority
KR
South Korea
Prior art keywords
ser
val
thr
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137006354A
Other languages
English (en)
Korean (ko)
Inventor
제라드 주라브스키
에프. 반슈로 자크
안-로르 플라마르
Original Assignee
베일러 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베일러 리서치 인스티튜트 filed Critical 베일러 리서치 인스티튜트
Publication of KR20130108295A publication Critical patent/KR20130108295A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020137006354A 2010-08-13 2011-08-12 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 Withdrawn KR20130108295A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37376310P 2010-08-13 2010-08-13
US61/373,763 2010-08-13
PCT/US2011/047633 WO2012021834A1 (en) 2010-08-13 2011-08-12 Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells

Publications (1)

Publication Number Publication Date
KR20130108295A true KR20130108295A (ko) 2013-10-02

Family

ID=45564978

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137006354A Withdrawn KR20130108295A (ko) 2010-08-13 2011-08-12 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제

Country Status (14)

Country Link
US (1) US20120039916A1 (https=)
EP (1) EP2603235A4 (https=)
JP (1) JP2013535508A (https=)
KR (1) KR20130108295A (https=)
CN (1) CN103328005A (https=)
AR (1) AR082686A1 (https=)
AU (1) AU2011289234B2 (https=)
BR (1) BR112013002940A2 (https=)
CA (1) CA2807585A1 (https=)
MX (1) MX2013001527A (https=)
RU (1) RU2013110889A (https=)
TW (1) TWI506035B (https=)
WO (1) WO2012021834A1 (https=)
ZA (1) ZA201301013B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240112401A (ko) * 2023-01-11 2024-07-19 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
JP2010530735A (ja) * 2007-05-03 2010-09-16 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 細胞内のｐｒｌ−１ポリペプチドまたはｐｒｌ−３ポリペプチドに結合する抗体
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
WO2013033104A1 (en) * 2011-08-29 2013-03-07 Baylor Research Institute CONTROLLING ALLERGY AND ASTHMA BY ACTIVATING HUMAN DCs VIA DECTIN-1 OR DECTIN-1 AND TOLL-LIKE RECEPTOR 2 (TLR2)
EP2822599A4 (en) * 2012-03-05 2015-12-23 Univ Duke VACCINE FORMULATION
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014031984A1 (en) * 2012-08-24 2014-02-27 Baylor Research Institute Immunological detection methods and compositions
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
CA2922937A1 (en) 2013-09-05 2015-03-12 Duke University Nav1.7 antibodies and methods of using the same
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
KR20160106170A (ko) * 2014-01-22 2016-09-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체 및 항체-부하된 수지상 세포 매개된 요법을 위한 방법 및 조성물
CN106659774A (zh) 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
EP3148575B1 (en) * 2014-06-02 2019-08-21 Baylor Research Institute Compositions for treating allergy and inflammatory diseases
BR112016030740A2 (pt) 2014-07-01 2018-02-20 Pfizer Inc. diacorpos heterodiméricos biespecíficos e seus usos
EP3166976B2 (en) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN104689313A (zh) * 2015-03-04 2015-06-10 中国科学院海洋研究所 大菱鲆cd83分子作为疫苗佐剂的应用
WO2016179034A2 (en) * 2015-05-01 2016-11-10 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
TN2018000112A1 (en) 2015-10-29 2019-10-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
HK1259294A1 (zh) * 2015-11-10 2019-11-29 耶鲁大学 用於治疗自身免疫疾病和癌症的组合物及方法
EP3389707B1 (en) 2015-12-15 2025-08-20 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunogenic construct comprising an ebv-cell antigen and a targeting moiety and applications thereof
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
WO2017152088A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
WO2018140831A2 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
IL312120B2 (en) 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Pharmaceutical compositions
EP3645043A4 (en) * 2017-06-28 2021-04-07 The Board of Trustees of the Leland Stanford Junior University METHODS AND COMPOSITIONS FOR DECTIN 2 STIMULATION AND CANCER IMMUNOTHERAPY
US20210369635A1 (en) * 2017-11-29 2021-12-02 Adaptive Phage Therapeutics, Inc. Novel methods of vaccination using icosahedral phage
RU2020131012A (ru) * 2018-02-28 2022-03-28 Ф. Хоффманн-Ля Рош Аг 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени
US12589140B2 (en) 2019-01-22 2026-03-31 The Brigham And Women's Hospital, Inc. Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
EP3947454A1 (en) 2019-03-27 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
WO2020243616A1 (en) * 2019-05-31 2020-12-03 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
JP2023502712A (ja) * 2019-11-21 2023-01-25 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
JP2023525140A (ja) 2020-05-13 2023-06-14 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｏｘ４０活性化特性を有する組換えタンパク質
WO2021239838A2 (en) 2020-05-26 2021-12-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
BR112022024221A2 (pt) 2020-06-02 2022-12-20 Arcus Biosciences Inc Anticorpos para tigit
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
CN111850006B (zh) * 2020-07-27 2022-04-22 齐鲁工业大学 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36865及应用
CA3200878A1 (en) 2020-11-12 2022-05-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
JP2023549555A (ja) * 2020-11-18 2023-11-27 パイオニア イミュノセラピューティクス インコーポレイテッド 抗ｍａｒｃｏ抗体及びその使用
EP4267176A1 (en) 2020-12-23 2023-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
CA3209251A1 (en) 2021-01-29 2022-08-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
WO2023081806A2 (en) * 2021-11-04 2023-05-11 The General Hospital Corporation Anti-mesothelin antibody reagents
KR20240103030A (ko) 2021-11-17 2024-07-03 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 범용 사르베코바이러스 백신
WO2024074571A1 (en) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection
EP4601682A1 (en) * 2022-10-13 2025-08-20 The Brigham & Women's Hospital, Inc. Methods and compositions for improving response to immunotherapy
WO2024216189A1 (en) * 2023-04-13 2024-10-17 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057915C (zh) * 1994-09-19 2000-11-01 中国医学科学院医药生物技术研究所 免疫佐剂
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US20070224205A1 (en) * 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
KR20090114430A (ko) * 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
MX2009008926A (es) * 2007-02-23 2009-09-14 Baylor Res Inst Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
NZ599777A (en) * 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
CA2730742C (en) * 2008-07-16 2017-05-23 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
AU2010222928B2 (en) * 2008-07-16 2012-11-29 Baylor Research Institute Antigen presenting cell targeted vaccines
DK2406286T3 (en) * 2009-03-10 2016-08-22 Baylor Res Inst Anti-cd40 antibodies and uses thereof
EP2406289B1 (en) * 2009-03-10 2017-02-22 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
MX2012012833A (es) * 2010-05-07 2012-11-30 Baylor Res Inst Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240112401A (ko) * 2023-01-11 2024-07-19 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
JP2013535508A (ja) 2013-09-12
WO2012021834A1 (en) 2012-02-16
TW201208696A (en) 2012-03-01
MX2013001527A (es) 2013-04-24
ZA201301013B (en) 2015-10-28
CA2807585A1 (en) 2012-02-16
RU2013110889A (ru) 2014-09-20
AR082686A1 (es) 2012-12-26
BR112013002940A2 (pt) 2019-09-24
TWI506035B (zh) 2015-11-01
EP2603235A1 (en) 2013-06-19
CN103328005A (zh) 2013-09-25
AU2011289234A1 (en) 2013-02-21
AU2011289234B2 (en) 2014-09-11
US20120039916A1 (en) 2012-02-16
EP2603235A4 (en) 2014-04-09

Similar Documents

Publication Publication Date Title
KR20130108295A (ko) 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
TW201247706A (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
KR102806206B1 (ko) 저-점도 항원 결합 단백질 및 이의 제조 방법
KR102890653B1 (ko) 항-cd33 항체, 항-cd33/항-cd3 이중특이성 항체, 및 이의 용도
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
DK2519543T3 (en) HETERODIMER BINDING PROTEINS AND USE THEREOF
KR102182485B1 (ko) 단백질 약물의 불활성화를 위한 항체 로커
AU2015292406B2 (en) Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
KR101963923B1 (ko) 이중특이적 t 세포 활성화 항원 결합 분자
TWI289668B (en) Therapeutic human anti-IL-1R1 monoclonal antibody
KR101901458B1 (ko) Ｔｃｒ 복합체 면역치료제
CN111954680B (zh) IL2Rβ/共同γ链抗体
KR20180099723A (ko) 항-tl1a/항-tnf-알파 이중특이적 항원 결합 단백질 및 그의 용도
KR20180081532A (ko) 암 치료용 조성물 및 방법
KR20150122761A (ko) Ｔ 세포 활성화 항원 결합 분자
KR20150122203A (ko) T 세포 활성화 이중특이적 항원 결합 분자
CN107056951A (zh) Cd86拮抗物多靶点结合蛋白
TW201217397A (en) Antibodies to MAdCAM
KR20220154710A (ko) 소형 유도 및 항법 제어(miniGNC) 항체-유사 단백질 및 이의 제조 및 사용 방법
CN107949575A (zh) Cys80缀合型免疫球蛋白
TW202216743A (zh) Ｉｌ－１０突變蛋白及其融合蛋白
CN114502151B (zh) 抗cd19抗体及其使用和制备方法
RU2834996C1 (ru) Антитела против cd19 и способы их применения и получения
RU2838544C1 (ru) МИНИАТЮРНЫЕ АНТИТЕЛОПОДОБНЫЕ БЕЛКИ УПРАВЛЕНИЯ И НАВИГАЦИОННОГО КОНТРОЛЯ (miniGNC) И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
HK40065811A (zh) 抗cd19抗体及其使用和制备方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130312

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid